Elevance Health's stock experienced a significant pre-market plunge of 5.57% on Wednesday, following the release of its second-quarter financial results.

While the health insurer reported adjusted earnings per share of $7.45 for the quarter, surpassing the Wall Street consensus estimate of $6.21, this figure represented a 15.7% decline compared to the $8.84 reported in the same period last year. The company also raised its full-year adjusted EPS guidance to at least $27.00.

The sharp decline in pre-market trading is attributed to investor concerns over the year-over-year earnings contraction and profit-taking activity. The stock had rallied strongly in the prior session, surging approximately 5.25% in pre-market trading as several investment banks raised their price targets ahead of the earnings report, suggesting that the positive quarterly beat may have been partially anticipated by the market.